CombiGene
Malin Almgren is an experienced professional with a strong background in health data sciences, research consultancy, and strategic partnerships. Currently serving as a Board Member for CombiGene, Redsense Medical, and Experia Nordic Oy, Almgren also holds the position of Chief Executive Officer at Schain Research, where a focus is placed on advancing knowledge in drug development through advanced analytics. Prior roles include Board Member at DP SERVICES AB and Director of Strategic Partnerships at TURN, along with an extensive research background as Assistant Professor at Karolinska Institutet. Almgren holds a PhD in Medicine from Karolinska Institutet and an MSc in Chemistry from Stockholm University.
This person is not in the org chart
This person is not in any teams
CombiGene
CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization under its own management or in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Nasdaq First North and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se . For further information, please visit www.combigene.com. CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme